本文選題：胰島素抵抗　切入點：脂肪細胞　出處：《南京醫(yī)科大學》2017年博士論文　論文類型：學位論文

【摘要】：目的:脂肪組織中巨噬細胞分泌的炎癥因子可明顯改變脂肪細胞功能,誘導炎癥反應,降低胰島素敏感性。然而,關于脂肪組織中巨噬細胞分泌的微囊泡在巨噬細胞和脂肪細胞間信號傳遞中的作用尚未明確。但已有研究發(fā)現(xiàn),單核巨噬細胞分泌的微囊泡可上調人呼吸道上皮細胞炎癥介質的合成,在炎性疾病的發(fā)生中起一定的作用。所以,本研究主要探討炎性巨噬細胞分泌的微囊泡對人脂肪細胞胰島素抵抗的影響。方法:通過刺激M1型和M2型THP-1巨噬細胞產生各自的微囊泡,將這些微囊泡分別與人的原代成熟脂肪細胞和由人前脂肪細胞分化而來的成熟脂肪細胞共培養(yǎng),然后通過Western Blot方法檢測人脂肪細胞中Akt磷酸化水平;運用2-NBDG評估人脂肪細胞對葡萄糖的攝取。同時,我們還提取了被處理的人脂肪細胞的質膜,通過Western Blot方法檢測細胞膜上GLUT4表達水平;通過核萃取和Western Blot方法檢測NF-κB核轉運水平。結果:與M2型巨噬細胞分泌的微囊泡(M2 MVs)相比,M1型巨噬細胞分泌的微囊泡(M1 MVs)可明顯減少人脂肪細胞中磷酸化Akt水平。通過2-NBDG檢測人脂肪細胞對糖的攝取,我們發(fā)現(xiàn)用M1 MVs處理人脂肪細胞后,人脂肪細胞對胰島素依賴的葡萄糖攝取減少,而用M2 MVs處理人脂肪細胞后,人脂肪細胞對胰島素依賴的葡萄糖攝取增加。與M2 MVs相比,用M1 MVs處理人脂肪細胞后,可引起人脂肪細胞NF-κB核轉位增加,Akt磷酸化和GLUT4膜轉運減少,而這些改變可被NF-κB的特異性抑制劑——BAY 11-7085逆轉。結論:促炎的M1型巨噬細胞分泌的微囊泡可能是肥胖引起的胰島素抵抗的原因之一,其機制可能是通過激活NF-κB,減少人脂肪細胞胰島素信號轉導,降低細胞葡萄糖攝取。目的:探討艾塞那肽對肥胖2型糖尿病患者內臟脂肪的影響。方法:將36名單用二甲雙胍治療血糖控制不達標的肥胖2型糖尿病患者隨機分別接受艾塞那肽+二甲雙胍治療(GLP-1組)或阿卡波糖+二甲雙胍治療(對照組)3個月。觀察兩組患者試驗前后內臟脂肪含量的變化,以及空腹血糖、糖化血紅蛋白、空腹胰島素、血脂、體重指數(shù)和炎癥因子的改變。結果:GLP-1組患者的內臟脂肪含量試驗后較試驗前明顯減少(前:17947±5804mm2后:13717士3628mm2,P=0.001),而對照組內臟脂肪含量試驗前后無明顯變化(P = 0.197)。試驗后,GLP-1組患者內臟脂肪含量較對照組更低(P=0.043)。兩組患者試驗后的血糖控制和胰島素抵抗較試驗前均明顯改善,HbA1c(GLP-1 組:前 9.72±1.38%后 7.09±0.60%,P0.001;對照組:前 9.46±1.25%后 7.42±0.84%,P0.001),LN(HOMA-IR)(GLP-1 組:前 1.58±0.40后 1.01±0.33,P0.001;對照組:前 1.53±0.57后 1.10±0.33,P=0.003)。但試驗后,兩組間HbA1c和LN(HOMA-IR)比較無明顯差異。GLP-1組試驗后TNF-α,IL-6和瘦素較試驗前明顯降低,脂聯(lián)素明顯升高(P0.05),而對照組試驗前后均無明顯改變。試驗后,兩組間TNF-α,IL-6和瘦素水平無明顯不同,而GLP-1組脂聯(lián)素水平較對照組更高(P = 0.025)。結論:艾塞那肽在控制血糖同時,還可減少肥胖糖尿病患者的內臟脂肪含量、改善肥胖患者的胰島素抵抗和炎癥狀態(tài)。
[Abstract]:Objective: inflammatory cytokines secreted by macrophages in adipose tissue can markedly alter adipocyte function, inducing inflammation, reduce insulin sensitivity. However, on macrophages in adipose tissue secretion were soaked in macrophages and adipocytes in signal transduction are not yet clear. But studies have found that the synthesis of microencapsulated mononuclear macrophage foam on the epithelial cells of human respiratory tract inflammatory mediators, play a role in inflammatory diseases. Therefore, this study focused on the inflammatory macrophage foam microcapsule effects on insulin resistance in human adipose cells. Methods: the vesicles through the stimulation of M1 type and M2 type THP-1 macrophages, these microvesicles were primary adipocytes and the differentiation of human preadipocytes to mature adipocytes were cultured, and then through the Western Blot Method for detection of human fat cells in Akt phosphorylation; use of glucose uptake in 2-NBDG assessment of fat cells. At the same time, we also extracted human adipocytes treated membrane, through the cell membrane to detect Western Blot method on the expression level of GLUT4; through nuclear extraction and Western Blot method to detect NF- kappa B nuclear translocation. Results: Microcystis secretion and M2 macrophages (M2 MVs) compared to the global, M1 type macrophage foam microcapsules (M1 MVs) can significantly reduce the human fat cells in Akt phosphate level. Based on the detection of glucose uptake in human adipocytes 2-NBDG, we found that M1 MVs treated human fat cells, glucose uptake of people fat cells to insulin dependent decrease, and M2 MVs in human adipocytes, glucose uptake in human adipose cells to insulin dependent increase. Compared with M2 MVs, M1 MVs treated fat cells, can cause Human fat cells NF- kappa B nuclear translocation increased Akt phosphorylation and GLUT4 membrane decreased, and these changes may be a specific inhibitor of NF- kappa B -- BAY 11-7085. Conclusion: the reversal of microencapsulated M1 macrophages inflammatory secretion may be one of the reasons for global obesity induced insulin resistance and its possible mechanism through the activation of NF- kappa B, reduced insulin signal transduction in fat cells, reduce the cell glucose uptake. Objective: To evaluate the effect of exenatide on type 2 diabetes mellitus patients with visceral fat obesity. Methods: 36 list with metformin insufficientlycontrolled blood glucose in obese patients with type 2 diabetes were randomized to receive exenatide and metformin the treatment (group GLP-1) or acarbose and metformin treatment (control group) for 3 months. To observe the changes of visceral fat content of two groups of patients before and after the test, and fasting blood glucose, glycosylated hemoglobin, fasting insulin, Blood lipid, body mass index and inflammatory factor changes. Results: visceral fat content test in GLP-1 group were significantly decreased after more tests before (before: 17947 + 5804mm2 13717 + 3628mm2, P=0.001), while the control group before and after the test of visceral fat content had no significant change (P = 0.197). After the test, patients in group GLP-1 visceral fat content is lower than the control group (P=0.043). The two groups of patients after the test of glucose control and insulin resistance test were significantly improved, HbA1c (group GLP-1: 9.72 + 1.38% 7.09 + 0.60%, P0.001; control group: 9.46 + 1.25% 7.42 + 0.84%, P0.001), LN (HOMA-IR) (group GLP-1: 1.58 + 0.40 1.01 + 0.33, P0.001; control group: 1.53 + 0.57 1.10 + 0.33, P=0.003). But after the experiment, two groups of HbA1c and LN (HOMA-IR) was not significantly different between.GLP-1 group after the test of TNF- alpha, IL-6 and leptin were tested decreased obviously adiponectin was significantly increased (P0.05 ), while the control group had no obvious change before and after the test. After the test, two groups of TNF- alpha, IL-6 and leptin levels were not significantly different, while adiponectin levels higher than the control group GLP-1 group (P = 0.025). Conclusion: exenatide in glycemic control at the same time, also can reduce the content of visceral fat in obese patients. Diabetes in obese patients, improve insulin resistance and inflammation.

【學位授予單位】：南京醫(yī)科大學
【學位級別】：博士
【學位授予年份】：2017
【分類號】：R58

【參考文獻】

相關期刊論文 前2條

1 Eun Kyung Choe;Donghee Kim;Hwa Jung Kim;Kyu Joo Park;;Association of visceral obesity and early colorectal neoplasia[J];World Journal of Gastroenterology;2013年45期

2 陳健;王沛堅;馬麗群;張莉莉;黎黎;王非;趙宇;王利娟;曹廷兵;劉道燕;祝之明;閆振成;;膳食辣椒素預防高脂飲食誘導的小鼠胰島素抵抗[J];第三軍醫(yī)大學學報;2013年07期

，

本文編號：1622140